Objective: Administration of caffeine citrate (caffeine) has been a central component of the treatment of apnea of prematurity. However, given its multiple pharmacologic effects, caffeine might be expected to produce hemodynamic changes in heart rate, stroke volume, cardiac output and vascular resistance.
Introduction
Caffeine citrate (caffeine), a trimethylxanthine, is widely used as first-line therapy in neonates to treat or prevent apnea of prematurity. The beneficial effects of caffeine in these contexts are widely documented in both randomized and observational trials. [1] [2] [3] However, caffeine has other physiologic effects, including stimulating the central nervous and cardiovascular system, 4 enhancing catecholamine secretion, 4 and increasing basal metabolic rate. 4 At the pharmacologic level, caffeine acts by blocking adenosine receptors A1 and A2a, increasing cyclic 3, 5 adenosine monophosphate by inhibiting phosphodiesterase, and translocating intracellular calcium. 5 At least plausibly, some of these pharmacologic actions might interact with regulation of systemic hemodynamics. Small studies with variable methodology have reported conflicting effects of caffeine on systemic blood pressure (BP), cardiac output (CO) and vascular resistance. However, no large study has looked systematically at the acute hemodynamic effects of caffeine in premature infants.
We performed a prospective observational study of the acute hemodynamic effects of administration of caffeine on stroke volume (SV), heart rate (HR), CO and BP.
Methods

Study design
We identified 31 infants in our neonatal intensive care unit (NICU) for whom caffeine had been ordered by the attending neonatologist (not one of the experimenters) as therapy or prophylaxis for apnea of prematurity. As our study was observational in nature, no constraints were put on the dose of caffeine citrate (5, 10, 20 mg kg À1 ), gestational age, birth weight or postnatal age of patient. All caffeine doses were administered intravenously over 15-20 min. For each infant, HR and arterial oxygen saturation were monitored continuously, and BP was determined either continuously by indwelling transducer or intermittently by cuff. CO was determined echocardiographically by integration of blood flow velocity at the aortic root (see below).
Measurement of hemodynamic parameters
We first assessed the presence of a patent ductus arteriosus (PDA) in each of our study patients using color Doppler. Any patient with a PDA was excluded from further study, as left ventricular output would not be an accurate measure of systemic blood flow (SBF) in the presence of either a right-to-left or left-to-right aorticpulmonary shunt.
Cardiac output was calculated using the standard echocardiographic method. A Hewlett-Packard 2500 ultrasound scanner with 7.5 MHz probe was used to determine aortic root diameter (AOD), measured in the parasternal long axis view by two-dimensional echocardiography, frame by frame between the bases of cusps at the end of the diastole. Aortic cross-sectional area (ACSA) was calculated using the formula 3:14 Ã ðAODÞ 2 =4. Because a small change in the AOD will change the CO exponentially and AOD is not likely to change between pre-and post-caffeine administration, we used the same AOD for both preand post-caffeine CO calculations. Aortic velocity time integral (VTI) was recorded in the apical view by continuous Doppler wave, where the cursor was placed across the aortic annulus close to the valve leaflets. Care was taken to align the Doppler beam with the long axis of the aorta, so that the maximal velocities are recorded and no correction for intercept angles was needed. Doppler waveforms were analyzed by the software of the ultrasound system (HP 2500) for peak velocity, mean velocity and average VTI. For each of the infants in the study, the average value of VTI five cardiac cycles was determined in the pre-and post-caffeine condition, and these average values were used in subsequent calculations of hemodynamic function. SV was calculated as the product of ACSA and VTI divided by body weight. CO was calculated as the product of HR and SV. Systemic vascular resistance (SVR) was calculated as the ratio of mean BP/CO.
The collection and analysis of hemodynamic data for the purposes of publication has been approved by the Internal Review Board of the Division of Biological Sciences at the University of Chicago. Parental consent was waived, in accordance with our IRB directives, as bedside echocardiography is standard medical care in our NICU.
Sample size estimation
The number of patients needed to confirm a 20% difference between pre-and post-caffeine CO using an estimation for the b (power) of 0.90 and P-value (a) of 0.05 was 25 patients (pre-and post-caffeine).
Statistical analysis
One caffeine administration per patient was analyzed. Hemodynamic values pre-and post-caffeine were compared statistically using both univariate analysis by Student's t-test for paired samples and nonparametric analysis (sign test).
Multivariate linear regression analysis was performed for the effects of covariates: gestational age, birth weight, postnatal age and dose of caffeine on the difference between pre-and post-caffeine values for each hemodynamic variable of interest. Because this was an observational study, no constraints were put on the dose of caffeine (5 mg kg
À1
, n ¼ 18; 10 mg kg À1 , n ¼ 12; 20 mg kg À1 , n ¼ 13), gestational age, birth weight or postnatal age of patient (ranges 1-38 days). Consequently, multivariate linear regression analyses were possible for each of these potential variables. Statistical significance for these analyses was accepted at an a-value of 0.05.
All data are presented as mean±standard deviation unless otherwise specified.
Results
Demographics
Gestational age of the 31 infants in our study population was 28.4 ± 2.8 (s.d.) weeks; birth weight was 1.19 ± 0.4 kg; day of life of caffeine administration was 9.2 ± 10.6 days; dose was 10.2±6.6 mg kg À1 . Post-caffeine measurements were obtained at 47 ± 20 min after caffeine administration.
Hemodynamic effects of caffeine
The hemodynamic effects of 31 doses of caffeine are summarized in Table 1 Administration of caffeine in premature infants V Soloveychik et al min and BP increased in 25 of 31 trials, by 4.1±5.8 mm Hg (all P<0.001). Caffeine had no significant effect on systemic vascular resistance. Multivariate linear regression revealed no significant effect of dose, birth weight, gestational age or postnatal age. Specifically, there was no tendency for either more mature, or more immature infants to respond differentially to caffeine. In total, 20 infants were <27 weeks, change in CO 209 ± 264, P<0.001. In total, 23 infants were >27 weeks, change in CO 173±197, P<0.001 (Table 2) .
Discussion
Caffeine is widely used in NICU care for prevention, or prophylaxis apnea of prematurity. It has been extensively studied in this role, and appears both effective and safe. In a large placebo-controlled study, caffeine toxicity (measured as tachycardia, tachypnea, jitteriness, tremors and unexplained seizures) was noticed in only 1.8% of preterm infants, with no statistical significance between the study and control groups, and no increase in mortality. 1 However, other aspects of caffeine's effects, in particular its effects on hemodynamic performance have not been well studied. We took advantage of the routine use of bedside echocardiographic assessments of CO in our NICU to evaluate in a prospective, systematic fashion the acute hemodynamic impact of caffeine administration.
We report here the largest study of which we are aware describing the acute hemodynamic effects of intravenous caffeine in premature infants. We note that caffeine increased left ventricular CO in 31 of 31 administrations, by an average of approximately 15%. Both SV and HR increased equally, by approximately 7%. BP rose significantly, by 4 mm Hg. Caffeine had no significant effect on systemic vascular resistance. Multivariate linear regression revealed no significant effects of birth weight, gestational age, chronologic age and dose. Though the statistical significance of the hemodynamic impact of caffeine is clear, we recognize that the clinical significance of these effects remains uncertain.
Previous studies, with smaller numbers and less rigorous measurement protocols, have reported conflicting cardiovascular effects of methylxanthines (either caffeine or aminophylline) in premature infants. Hoecker et al. 4, 6 examined the effect of caffeine loading in two regimens in two groups of 16 infants and showed no change in left ventricular CO (LVCO), HR or BP when measured 1 and 2 h after in one regimen and 1, 2 and 20 h later in the second regimen. Walther et al. 5 showed an increase in LVCO and HR in 11 infants treated with aminophylline, however postaminophylline determinations were made 4 h after maintenance dose. SV was increased by 15% only in the first 3 days of treatment, but returned to base line by the seventh day of treatment. Walther et al. 7 also showed an increase in LVCO (B27%), SV (B35%) and BP in 10 treated infants, compared to controls, measured 1 h before the maintenance dose. An increase in LVCO (B47%), SV (B44%) and HR was also shown in a study of theophylline effect on 15 infants by Fesslová et al. 8 performed 30 min after administration.
The effect of caffeine on LVCO and SV noted in our patients was more significant, and more consistent, than any previously described pharmacologic agent in premature infants. Previous studies describing the pharmacological effects of dopamine, dobutamine, milrinone, epinephrine or hydrocortisone have not shown consistent changes in the LVCO and SV. [9] [10] [11] [12] [13] [14] [15] [16] Hydrocortisone, 9 commonly used to increase BP in infants unresponsive to dopamine, failed to increase LVCO significantly in a study of 15 hypotensive infants. The hemodynamic effect of dopamine has been examined in several studies: A trend of increasing RVCO, did not reach statistical significance, with significant increase of the shortening fraction in 8 hypotensive premature infants; 10 in 50 hypotensive patients treated with dopamine, LVCO dropped in 40, compared to 10 others in whom LVCO increased 11: BP did increase in the low LVCO group, with concomitant increase in the SVR. When comparing dopamine and dobutamine in the treatment of low SBF in 42 patients, 40% of patients did not respond at all, while dobutamine achieved better SBF increase and dopamine achieved BP increase in the others. 12 Dopamine was more effective than dobutamine in raising BP in 20 hypotensive infants however dopamine did not increase LVCO. 13 Both dopamine and dobutamine failed to increase myocardial contractility in 106 infants with low SBF in the first day of life, with dopamine increasing LV stress.
14 Milrinone failed to increase right ventricular CO (RVCO) in a prospective trial. 16 In sum, intravenous caffeine administration appears to increase CO in normotensive premature infants by approximately 15%. This effect appears to be reliable, and appears to be insensitive to variations in birth weight, gestational age, chronologic age and dose. The increase in CO is mediated equally by an increase in SV and HR. These observations provoke an intriguing hypothesisFif Abbreviations: BP, blood pressure (mm Hg); CO, cardiac output (ml min À1 per kg); HR, heart rate (beats per min); SV, stroke volume (ml per beat); SVR, systemic vascular resistance (mm Hg/ml min À1 per kg).
Administration of caffeine in premature infants V Soloveychik et al caffeine improves CO and BP in relatively stable infants, might there be a role for caffeine in improving hemodynamics in sick neonates?
